Cargando…
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the curr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209358/ https://www.ncbi.nlm.nih.gov/pubmed/35696053 http://dx.doi.org/10.1007/s40265-022-01728-w |
_version_ | 1784729937052172288 |
---|---|
author | Palandri, Chiara Santini, Lorenzo Argirò, Alessia Margara, Francesca Doste, Ruben Bueno-Orovio, Alfonso Olivotto, Iacopo Coppini, Raffaele |
author_facet | Palandri, Chiara Santini, Lorenzo Argirò, Alessia Margara, Francesca Doste, Ruben Bueno-Orovio, Alfonso Olivotto, Iacopo Coppini, Raffaele |
author_sort | Palandri, Chiara |
collection | PubMed |
description | Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the current guidelines are derived from small non-randomized studies, case series, or simply from the consensus of experts. Guideline-directed therapy of HCM includes non-selective drugs such as disopyramide, non-dihydropyridine calcium channel blockers, or β-adrenergic receptor blockers, mainly used in patients with symptomatic obstruction of the outflow tract. Following promising preclinical studies, several drugs acting on potential HCM-specific targets were tested in patients. Despite the huge efforts, none of these studies was able to change clinical practice for HCM patients, because tested drugs were proven to be scarcely effective or hardly tolerated in patients. However, novel compounds have been developed in recent years specifically for HCM, addressing myocardial hypercontractility and altered energetics in a direct manner, through allosteric inhibition of myosin. In this paper, we will critically review the use of different classes of drugs in HCM patients, starting from “old” established agents up to novel selective drugs that have been recently trialed in patients. |
format | Online Article Text |
id | pubmed-9209358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92093582022-06-22 Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside Palandri, Chiara Santini, Lorenzo Argirò, Alessia Margara, Francesca Doste, Ruben Bueno-Orovio, Alfonso Olivotto, Iacopo Coppini, Raffaele Drugs Review Article Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease has hampered the design and conduct of large, randomized trials in the last 50 years, and most of the indications in the current guidelines are derived from small non-randomized studies, case series, or simply from the consensus of experts. Guideline-directed therapy of HCM includes non-selective drugs such as disopyramide, non-dihydropyridine calcium channel blockers, or β-adrenergic receptor blockers, mainly used in patients with symptomatic obstruction of the outflow tract. Following promising preclinical studies, several drugs acting on potential HCM-specific targets were tested in patients. Despite the huge efforts, none of these studies was able to change clinical practice for HCM patients, because tested drugs were proven to be scarcely effective or hardly tolerated in patients. However, novel compounds have been developed in recent years specifically for HCM, addressing myocardial hypercontractility and altered energetics in a direct manner, through allosteric inhibition of myosin. In this paper, we will critically review the use of different classes of drugs in HCM patients, starting from “old” established agents up to novel selective drugs that have been recently trialed in patients. Springer International Publishing 2022-06-13 2022 /pmc/articles/PMC9209358/ /pubmed/35696053 http://dx.doi.org/10.1007/s40265-022-01728-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Article Palandri, Chiara Santini, Lorenzo Argirò, Alessia Margara, Francesca Doste, Ruben Bueno-Orovio, Alfonso Olivotto, Iacopo Coppini, Raffaele Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title | Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title_full | Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title_fullStr | Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title_full_unstemmed | Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title_short | Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside |
title_sort | pharmacological management of hypertrophic cardiomyopathy: from bench to bedside |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209358/ https://www.ncbi.nlm.nih.gov/pubmed/35696053 http://dx.doi.org/10.1007/s40265-022-01728-w |
work_keys_str_mv | AT palandrichiara pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT santinilorenzo pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT argiroalessia pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT margarafrancesca pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT dosteruben pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT buenoorovioalfonso pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT olivottoiacopo pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside AT coppiniraffaele pharmacologicalmanagementofhypertrophiccardiomyopathyfrombenchtobedside |